Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG601 in Adult Men With Fragile X Syndrome
NCT06413537Phase 2Completed
- Sponsor
- Spinogenix
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SPG601 in Fragile X syndrome (FXS) (2 arms), sponsored by Spinogenix. Primary endpoints: Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician at 15 days, Clinical Global Impressions Improvement Scale as Determined by the Caregiver at 15 days and 2 more. Started Jul 2024; status: completed.
02
Drugs
SPG601
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT06413537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413537.